Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Biotechnology

Healthcare
$2.43 +2.06%

+$0.05 today

Market cap
$309.51M
Beta
0.75
P/E (TTM)
-4.9
EPS (TTM)
-$0.45
52W Low $0.62High $4.31

Volume 4.55M

Average 0.40M

NAUT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Nautilus Biotechnology, Inc.NASDAQ: NAUT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 126.63M shares rose 0.4% year over year, in line with the +0.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +0.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
126.63M+0.3% QoQ
Last fiscal yearDec 2025
126.26M+0.7% YoY
LTMMar 2026
126.35M+0.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year+0.7%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
126.26M USD
Year-over-year change
+0.7%
4-year CAGR
+10.6%

Weighted Avg Shares vs competitors

How NAUT compares with its peers on the latest reported figures

  • NAUT's LTM Mar 2026 weighted avg shares of 126.35M shares is the 3rd highest of the 11 companies compared; the peer median is 51.72M shares.
  • Its year-over-year change of +0.5% is the lowest of 11, against a peer median of +18.9%.
  • Over three fiscal years its annual growth of +0.4% compares with a peer median of +17.0%.
NAUT Competitors Peer median
Weighted Avg Shares for NAUT and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
ZURAZura Bio LimitedLTM Mar 202698.81M +34.9%+76.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
PYXSPyxis Oncology, Inc.LTM Mar 202662.52M +2.9%+23.4%
IMRXImmuneering CorporationLTM Mar 202640.92M +29.8%+18.6%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding NAUT) 51.72M+18.9%+17.0%

Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue2.84M3.42M5.71M6.35M6.47M
Gross Profit(2.84M)(3.42M)(5.71M)(6.35M)(6.47M)
Gross Margin—————
Research & Development26.51M36.46M47.25M50.48M41.11M
Selling, General & Admin21.15M23.75M28.9M31M25.73M
Operating Expenses47.66M60.2M70.45M75.12M60.37M
Depreciation & Amortization2.84M3.42M1.85M6.35M6.47M
EBITDA(47.47M)(54.51M)(61.83M)(64.43M)(52.54M)
EBITDA Margin—————
Operating Income(50.5M)(63.62M)(76.15M)(81.48M)(66.84M)
Operating Margin—————
Interest Income329K5.82M12.55M10.78M7.87M
Interest Expense05.82M000
Other Income / Expenses183K5.69M12.48M10.7M7.84M
Income Before Tax(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(50.32M)(57.92M)(63.68M)(70.78M)(59M)
Net Margin—————
EPS (Basic)(0.60)(0.46)(0.51)(0.56)(0.47)
EPS (Diluted)(0.60)(0.46)(0.51)(0.56)(0.47)
Weighted Avg Shares84.46M124.59M124.92M125.43M126.26M
Weighted Avg Shares (Diluted)84.46M124.59M124.92M125.43M126.26M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Intrinsic Alpha fair value

Locked

Current Price

$2.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.